SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
APPLICATION FOR CLINICAL TRIAL ON TQF6422 INJECTION "ACTRII A/B MONOCLONAL ANTIBODY" APPROVED BY THE NMPA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that TQF6422 injection ("**ActRII A/B Monoclonal Antibody**"), a national Category 1 innovative drug independently developed by the Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("**CTTQ**"), has received the approval for clinical trial from the Center for Drug Evaluation (CDE) of the China's National Medical Products Administration (NMPA) for weight management in adult patients with obesity, or in overweight adults with at least one weight-related comorbidity.

TQF6422 is a fully human IgG1 monoclonal antibody targeting ActRII A/B. By specifically binding to the ActRII A/B receptor, it potently blocks signal transduction mediated by ligands such as activin and myostatin, promoting skeletal muscle growth while enhancing lipolysis, thereby achieving the dual therapeutic potential of "fat loss and muscle gain."

ActRII comprises two major subtypes, ActRII A and ActRII B, which are mainly expressed in adipocytes and muscle cells. In adipocytes, binding of activin ligands to ActRII receptors promotes lipid storage and visceral fat accumulation, serving as a key driver of visceral adiposity and the development of obesity. In muscle cells, ligands such as activins and myostatin act on ActRII receptors to directly inhibit muscle growth and lead to muscle atrophy. Conversely, blockade of this signaling pathway can prevent atrophy and promote lean mass accretion. Therefore, targeting the ActRII pathway has the potential to simultaneously reduce fat mass and increase lean body mass.

This approval is based on the preclinical study data for TQF6422[1]. The study results show:

1. Superior In Vitro Activity and Pharmacodynamic Properties

TQF6422 exhibits more than 10-fold greater in vitro activity than benchmark molecules and achieves superior fat reduction and lean body mass maintenance at lower doses across various animal pharmacodynamic models.

2. Synergistic Effects with GLP-1, Delivering Dual Benefits of Fat Loss and Muscle Gain

In an obese monkey model, combination therapy with TQF6422 and semaglutide resulted in 1.5 to 2 times greater fat reduction and 72% to 85% higher retention of lean body mass compared to semaglutide monotherapy. Fat reduction accounted for 93% of total weight loss, demonstrating the potential for synergistic effects when used in combination with GLP-1 receptor agonists.

3. Favorable Pharmacokinetic and Safety Profiles

Pharmacokinetic studies show that TQF6422 has a significantly prolonged half-life, supporting the exploration of longer dosing intervals. Regarding safety, all tested doses demonstrated good tolerability, and no treatment-related adverse findings were observed.

Obesity is a complex chronic metabolic disease associated with an increased risk of various metabolic disorders, cardiovascular diseases, respiratory diseases, malignancies and mental health disorders. While current mainstream weight-loss treatments can achieve significant weight loss, the loss of muscle mass that accompanies this process is receiving increasing attention[2-3]. A reduction in muscle mass may affect basal metabolism, insulin sensitivity and long-term weight management outcomes. Consequently, the clinical goal of weight management is shifting from mere weight change to the comprehensive improvement of body composition indicators such as fat mass, lean body mass and metabolic health.

TQF6422, a novel ActRII A/B Monoclonal Antibody independently developed by CTTQ, is distinguished by its dual mechanism of action that concurrently promotes adipose reduction and skeletal muscle accretion. This unique profile holds the potential to address the current limitations of existing weight-loss therapies, offering patients with obesity or overweight a more comprehensive and effective weight management option. In parallel, the Group has strategically positioned a diversified pipeline in this therapeutic area, including oral GLP-1RA, INHBE siRNA, and GLP-1 transdermal patches, reflecting its sustained commitment to advancing superior weight management solutions.

Sources:

[1] TQ-lm-10: A Fully Human ActR Ⅱ A/B Antibody Improves Weight Loss Quality by Preserving Lean Mass and Enhancing Fat Reduction, ECO 2026.

[2] Dlamini M, Khathi A. Prediabetes-associated changes in skeletal muscle function and their possible links with diabetes: a literature review[J]. International Journal of Molecular Sciences, 2023, 25(1): 469.

[3] Bikou A, Dermiki-Gkana F, Penteris M, et al. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials[J]. Expert Opinion on Pharmacotherapy, 2024, 25(5): 611-619.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 21 August 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.